Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen builds $250m biosimilars plant in Iceland

This article was originally published in Scrip

Executive Summary

Alvotech, an Iceland-based sister company of the privately owned US generics firm Alvogen, is to invest $250m in a biosimilars development and manufacturing facility in Reykjavik, Iceland. The plant will produce biosimilar monoclonal antibodies for marketing by Alvogen, which currently markets biosimilars in some parts of the world through alliances with other firms, including Hospira.

You may also be interested in...



Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China

With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.

INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future

Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.

INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future

Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel